Results 161 to 170 of about 10,751 (182)

Ramucirumab

Reactions Weekly, 2017
openaire   +2 more sources

Ramucirumab

2015
Lordick, Florian, Thuss-Patience, Peter, Wörmann, Bernhard, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Bokemeyer, Carsten, Batran, Salah-Eddin Al-   +6 more
openaire   +1 more source

FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab as Second-Line Therapy for Patients With Advanced or Metastatic Gastroesophageal Adenocarcinoma With or Without Prior Docetaxel – Results From the Phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

European Journal of Cancer, 2022
Daniel Pink, Sylvie Lorenzen, Thomas J Ettrich   +2 more
exaly  

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Journal of Thoracic Oncology, 2021
Rafael Santana-Davila, Nicolas Penel, Gu Mi   +2 more
exaly  

Ramucirumab

Reactions Weekly
  +6 more sources

Phase I Study of Every 2- or 3-Week Dosing of Ramucirumab, a Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Annals of Oncology, 2015
R B Cohen, R B Cohen, C J Sweeney
exaly  

Ramucirumab Combined With FOLFOX as Front-Line Therapy for Advanced Esophageal, Gastroesophageal Junction, or Gastric Adenocarcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Annals of Oncology, 2016
Z A Wainberg, S R Alberts, J C Bendell
exaly  

Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression on Platinum-Based Therapy (REVEL): A Multicentre, Double-Blind, Randomised Phase 3 Trial

Lancet, The, 2014
Sergey Orlov, Edward B Garon, Michael Thomas   +2 more
exaly  

Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients With Metastatic Colorectal Cancer From RAISE, a Global, Randomized, Double-Blind, Phase III Study

Annals of Oncology, 2018
Josep Tabernero Caturla, Rocío García-Carbonero, György Bodoky   +2 more
exaly  

Randomized Phase II Study of Modified FOLFOX-6 in Combination With Ramucirumab or Icrucumab as Second-Line Therapy in Patients With Metastatic Colorectal Cancer After Disease Progression on First-Line Irinotecan-Based Therapy

Annals of Oncology, 2016
R Burkes, J Bendell, F Nasroulah
exaly